A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
0.0
The BRCA Founder Outreach (BFOR) Study is a new research initiative. BFOR seeks to increase access to testing for one of the most common tests for hereditary cancer, BRCA genetic mutations. These mutations of BRCA genes are associated with greater risks for several types of cancer, including breast, ovarian, and prostate …
To confirm the efficacy of OTL38 in combination with fluorescent light to detect additional Folate Receptor-positive (FR+) ovarian cancer lesions
Patients with metastatic breast cancer, that is biopsy proven or clinically documented by standard imaging (e.g. CT, MRI, Bone Scan, Ultrasound, FDG PET/CT), may be eligible for this study. Patients may participate in this study, if they are at least 18 years of age. We anticipate enrolling up to 30 …
Since its emergence, SARS-Cov2 has rapidly and widely spread across the globe due to lack of prior protective immunity in the human species. With widespread mitigation measures, all efforts focused on generating effective vaccination strategies that will provide herd immunity and protect the most vulnerable populations. However, there is very …
This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian …
This is a pragmatic randomized clinical trial in which patients with locally advanced breast cancer will be randomized to either proton or photon therapy and followed longitudinally for cardiovascular morbidity and mortality, health-related quality of life (HRQOL), and cancer control outcomes. We hypothesize that proton therapy, as part of multi-modality …
The main purpose of this study is to examine the efficacy of adding itacitinib (also known as INCB039110) to pembrolizumab in patients with previously untreated metastatic non-small cell lung cancer.
Congrats! You have your own personal workspace now.